News | March 20, 2008

Cordis Gets FDA 510(k) for Stent Biliary System

March 21, 2008 - Cordis Corp. has received 510(k) marketing clearance from the FDA for the S.M.A.R.T. Nitinol Stent Transhepatic Biliary System for lengths of 120 mm and 150 mm, the company reported at the 33rd Annual Scientific Meeting of the Society of Interventional Radiology (SIR) meeting.

These stents are indicated for use in the palliative treatment of malignant strictures in the biliary tree that can restrict the flow of digestive fluids and compromise digestion.

Available for the first time in the U.S. in the new lengths, the stents have demonstrated accurate stent placement, which may decrease the need for additional stents to cover the full narrowing of the bile duct. The safety and effectiveness of this device for use in the vascular system have not been established.

For more information: www.cordis.com


Additional Content

News | Interventional Radiology

Nov. 12, 2025 — On Nov. 11, Huntsman Cancer Institute at the University of Utah (the U) opened its first specialized ...

Home November 13, 2025
Home
News | Interventional Radiology

Jan. 28, 2025 — Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular ...

Home January 29, 2025
Home
News | Interventional Radiology

January 9, 2024 — Proceedings from an expert consensus roundtable that discussed the benefits of intravascular ...

Home January 09, 2024
Home
News | Interventional Radiology

February 23, 2023 — Few adverse events are connected to the use of inferior vena cava (IVC) filters to help prevent deep ...

Home February 23, 2023
Home
Subscribe Now